FDA Approves SUNLENCA — Gilead Sciences, Inc.

# FDA Approves Gilead Sciences' SUNLENCA (lenacapavir sodium), a First-in-Class HIV Treatment Gilead Sciences, Inc. received FDA approval for SUNLENCA (lenacapavir sodium), positioning the company to capture a significant share of the growing long-acting HIV treatment market and potentially reshaping competitive dynamics in antiviral therapy. The approval of this first-in-class capsid inhibitor could drive substantial revenue growth for Gilead while setting a new treatment standard that may pressure competitors to accelerate their own long-acting HIV pipeline candidates.